# Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)

> **NCT05738616** · PHASE3 · RECRUITING · sponsor: **Wen Tianfu** · enrollment: 196 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** Lenvatinib combined with TACE and Camrelizumab

## Key facts

- **NCT ID:** NCT05738616
- **Lead sponsor:** Wen Tianfu
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-10
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 196 (ESTIMATED)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05738616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05738616, "Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05738616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*